Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 5/20 | 0.49 |
| ▸ | VCP | P55072 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6752278 | 0.85 | FFAR1 (0.50) | FFAR1FFAR4GRM5VCPEGLN1 | |
| SCHEMBL5592873 | 0.82 | VCP (0.68) | FFAR1FFAR4GRM5VCPNPSR1 | |
| SCHEMBL31614569 | 0.82 | VCP (0.68) | FFAR1FFAR4GRM5VCPNPSR1 | |
| SCHEMBL28119432 | 0.79 | FFAR1 (0.47) | FFAR1VCPNPSR1 | |
| SCHEMBL5593355 | 0.79 | VCP (0.73) | FFAR1FFAR4GRM5VCPNPSR1 | |
| SCHEMBL29961750 | 0.79 | FFAR1 (0.49) | FFAR1FFAR4GRM5VCPEGLN1 | |
| SCHEMBL28506510 | 0.79 | FFAR1 (0.49) | FFAR1FFAR4GRM5VCPEGLN1 | |
| SCHEMBL30469481 | 0.79 | GRM5 (0.69) | FFAR1FFAR4GRM5 | |
| SCHEMBL30469478 | 0.79 | GRM5 (0.69) | FFAR1FFAR4GRM5 | |
| SCHEMBL4562089 | 0.79 | GRM5 (0.69) | FFAR1FFAR4GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1153024-B1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2004-04-28 | — | — | EP | claimed |
| JP-2002537300-A | — | — | 2002-11-05 | — | — | JP | claimed |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-02-07 | — | — | US | claimed |
| EP-1153024-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2001-11-14 | — | — | EP | claimed |
| WO-2000049018-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | claimed |
| CN-107353194-A | A kind of preparation method of propine acid compounds | 大连理工大学 | 2017-11-17 | — | — | CN | disclosed |
| US-7300939-B2 | Substituted 1-propiolylpiperazine compounds, their preparation and use | GRUENENTHAL GMBH (DE) | 2007-11-27 | — | — | US | disclosed |
| US-20070112011-A1 | Substituted 1-propiolylpiperazine compounds, their preparation and use | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| CN-1217943-C | New use and novel N-azabicyclo-amide derivatives | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | CN | disclosed |
| US-6767906-B2 | INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. | NOVARTIS AG (CH) | 2004-07-27 | — | — | US | disclosed |
| EP-1153024-B1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2004-04-28 | — | — | EP | disclosed |
| CN-1423651-A | Novel use and novel N-azabicyclo-amide derivatives | ASTRAZENECA AB (SE) | 2003-06-11 | — | — | CN | disclosed |
| US-6177438-B1 | ANALGESICS, DIURETICS, ANTITUSSIVE AGENTS | TORAY INDUSTRIES, INC. (JP) | 2001-01-23 | — | — | US | disclosed |
| EP-0663401-B1 | MORPHINAN DERIVATIVE AND MEDICINAL USE | TORAY INDUSTRIES (JP) | 2000-06-07 | — | — | EP | disclosed |
| EP-0657163-B1 | ANTITUSSIVE | TORAY INDUSTRIES (JP) | 1998-10-14 | — | — | EP | disclosed |
| US-5739145-A | MORPHINAN DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0663401-A1 | MORPHINAN DERIVATIVE AND MEDICINAL USE | TORAY INDUSTRIES, INC. (JP) | 1995-07-19 | — | — | EP | disclosed |
| EP-0657163-A1 | ANTITUSSIVE | TORAY INDUSTRIES, INC. (JP) | 1995-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | FFAR1 350/4885FFAR4 1021/4885GRM5 646/4885 |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | CDK14, CDK1, CCNB1 | FFAR1 4790/4885FFAR4 4499/4885GRM5 4010/4885 |
| US-20070112011-A1 | Substituted 1-propiolylpiperazine compounds, their preparation and use | GRM5, GRIK5, GRM1 | FFAR1 305/4885FFAR4 728/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.